UroGen Pharma CMO Mark Schoenberg Sells $400,000 in Stock Following 191% Share Surge
核心洞察
UroGen Pharma Chief Medical Officer Mark Schoenberg sold 10,000 ordinary shares for $400,000 on July 9, 2026, under a pre-established Rule 10b5-1 trading plan.
The sale occurred with UroGen's market capitalization at $2.0 billion and shares priced at $40.23, following a 191.31% one-year stock appreciation.
Schoenberg retains 119,763 ordinary shares directly following the transaction, which represents the concluding trade of the August 2025 trading plan schedule.
UroGen Pharma's Chief Medical Officer Mark Schoenberg sold 10,000 ordinary shares of the company on July 9, 2026, realizing approximately $400,000 in total value, according to a Securities and Exchange Commission Form 4 filing. The transaction was executed under a pre-established Rule 10b5-1 trading plan adopted on August 15, 2025, and represents the concluding transaction of that plan's schedule.
The disposition occurred with UroGen's market capitalization at $2.0 billion, as shares closed at $40.23 on the transaction date. The sale follows a period of remarkable share price appreciation, with the company's stock delivering a 191.31% one-year total return.
Transaction Details and Remaining Holdings
Following the sale, Schoenberg continues to hold 119,763 ordinary shares directly, maintaining a significant equity stake in the biotechnology company. The Rule 10b5-1 trading plan under which the sale was executed provides for automated execution, insulating the transaction from discretionary timing concerns.
This sale follows a pattern of insider transactions by Schoenberg. A prior SEC filing from June 2026 disclosed the sale of 5,222 ordinary shares for approximately $143,000 at a weighted average price of around $27.30. That earlier transaction reflected a two-step process in which Schoenberg exercised 10,000 options and immediately sold 5,222 shares for liquidity, with the remainder held as ordinary shares. Since May of the prior year, Schoenberg executed seven sell transactions, with his direct holdings declining by 25.81% over that period.
Financial and Commercial Context
UroGen Pharma reported trailing 12-month revenue of $140.5 million against a net loss of $133.2 million, underscoring the company's continued investment in research and development alongside commercial scaling efforts.
The company's commercial portfolio is anchored by two key products: Zusduri (搜索), a sustained-release mitomycin formulation for non-muscle invasive bladder cancer (搜索), and Jelmyto, a treatment for low-grade upper tract urothelial cancer (搜索). First-quarter results showed Jelmyto sales rising 7% year-over-year to $21.7 million, representing approximately 42.5% of total first-quarter revenue. Zusduri demonstrated stronger momentum, with first-quarter sales jumping 109% year-over-year to $29.2 million.
Both products leverage UroGen's proprietary RTGel reverse thermal gelation hydrogel technology platform, which serves as the foundation for the company's pipeline strategy targeting urothelial and specialty cancers.
Generic Competition on the Horizon
On June 2, 2026, UroGen reached a settlement with Teva Pharmaceuticals regarding a generic version of Jelmyto. Under the terms of the agreement, Teva will receive a non-exclusive license to sell generic Jelmyto beginning September 15, 2030. This settlement introduces a defined timeline for potential generic erosion of Jelmyto revenues, though the multi-year runway provides UroGen with a window to continue growing Zusduri (搜索) and advancing its pipeline candidates, including UGN-102 and UGN-301.
Company Positioning
UroGen Pharma operates as a commercial-stage biotechnology company focused on developing and commercializing innovative therapies for urinary tract cancers. The company targets urologists, oncologists, and healthcare institutions treating patients with non-muscle invasive urothelial cancers. With its proprietary RTGel platform and established commercial infrastructure, UroGen is positioned as a differentiated player in the niche urothelial cancer treatment market, aiming to address significant unmet medical needs in the urology and oncology sectors.